Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the popular weight-loss drug, Wegovy. The Danish pharmaceutical giant and Hims & ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Hims & Hers (HIMS) is bringing access to its comprehensive weight loss program to the UK. After a detailed clinical ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

Hims & Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept. 9, addressed to the ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential ...

HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to ...